Buscar
Black Diamond Therapeutics Inc
BDTXAñadir a la lista de seguimiento
1.690USD
-0.025-1.46%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
96.84MCap. mercado
PérdidaP/E TTM
Más Datos de Black Diamond Therapeutics Inc Compañía
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Información de Black Diamond Therapeutics Inc
Símbolo de cotizaciónBDTX
Nombre de la empresaBlack Diamond Therapeutics Inc
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoVelleca (Mark A)
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección245 First Street, 18Th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16174175868
Sitio Webhttps://www.blackdiamondtherapeutics.com/
Símbolo de cotizaciónBDTX
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoVelleca (Mark A)
Ejecutivos de Black Diamond Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Black Diamond Therapeutics Inc?
Los cinco principales accionistas de Black Diamond Therapeutics Inc son: Dr. Ali Behbahani, M.D.
¿Cuántas instituciones poseen acciones de Black Diamond Therapeutics Inc (BDTX)?
A fecha de 2026Q1, 265 instituciones poseen acciones de Black Diamond Therapeutics Inc, con un valor de mercado combinado de aproximadamente 45.02M, lo que representa el 78.72% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -14972289.00.